LSV Asset Management Raises Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

LSV Asset Management increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 73.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 501,303 shares of the medical equipment provider’s stock after purchasing an additional 211,513 shares during the quarter. LSV Asset Management owned approximately 0.72% of Lantheus worth $31,201,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Westfield Capital Management Co. LP lifted its position in shares of Lantheus by 20.8% during the fourth quarter. Westfield Capital Management Co. LP now owns 1,563,181 shares of the medical equipment provider’s stock valued at $96,917,000 after buying an additional 268,790 shares during the last quarter. Reinhart Partners LLC. lifted its position in Lantheus by 8.4% during the first quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider’s stock valued at $91,517,000 after acquiring an additional 114,110 shares during the last quarter. American Century Companies Inc. boosted its stake in Lantheus by 41.9% in the third quarter. American Century Companies Inc. now owns 1,300,904 shares of the medical equipment provider’s stock valued at $90,387,000 after acquiring an additional 384,093 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Lantheus by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider’s stock worth $52,077,000 after purchasing an additional 7,590 shares during the last quarter. Finally, Balyasny Asset Management L.P. increased its position in shares of Lantheus by 8.2% during the fourth quarter. Balyasny Asset Management L.P. now owns 790,649 shares of the medical equipment provider’s stock worth $49,020,000 after purchasing an additional 60,240 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH traded down $0.20 on Friday, hitting $123.42. 2,412,419 shares of the company’s stock traded hands, compared to its average volume of 1,057,337. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $124.90. The firm’s 50-day moving average price is $81.01 and its two-hundred day moving average price is $67.35. The firm has a market capitalization of $8.55 billion, a PE ratio of 18.84 and a beta of 0.51.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, beating the consensus estimate of $1.40 by $0.11. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. The business had revenue of $369.98 million during the quarter, compared to analysts’ expectations of $349.46 million. As a group, analysts expect that Lantheus Holdings, Inc. will post 6.46 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on LNTH shares. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Truist Financial raised their price target on Lantheus from $96.00 to $141.00 and gave the stock a “buy” rating in a report on Thursday. JMP Securities upped their price objective on shares of Lantheus from $100.00 to $130.00 and gave the company an “outperform” rating in a report on Wednesday. SVB Leerink lifted their target price on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, Mizuho lifted their target price on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $113.86.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the sale, the chief accounting officer now directly owns 62,898 shares in the company, valued at approximately $4,836,227.22. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $76.89, for a total transaction of $26,219.49. Following the completion of the transaction, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the transaction, the director now directly owns 23,340 shares of the company’s stock, valued at $1,848,294.60. The disclosure for this sale can be found here. In the last ninety days, insiders sold 44,799 shares of company stock worth $3,748,151. Company insiders own 1.50% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.